TCR2 Therapeutics Inc.
TCRR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.18 | -2.08 | -0.05 |
| FCF Yield | -303.03% | -52.64% | -7.38% | -15.01% |
| EV / EBITDA | -0.67 | 0.20 | -11.50 | -4.67 |
| Quality | ||||
| ROIC | -79.01% | -32.46% | -29.01% | -31.98% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.82 | 0.85 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -25.64% | -45.61% | -41.26% | -128.51% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | 2.02 | 1.40 | 1.29 |
| Interest Coverage | -2.61 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |